US5213570A
Expired / Lapsed
US
⏱️ 0.0 years remaining
System and method for oxygenation of the pericardium
Assignee: Mallinckrodt Inc
•
Filing: 1990-12-14
•
Granted: 1993-05-25
•
Expires: 2010-12-14
Abstract
Abstract The present invention relates to a system and method for oxygenation of ischemic tissue. In particular, the present invention relates to a system and method for supplying oxygen to the myocardium of the heart through means other than the coronary arteries. The system of the present invention comprises a catheter which may be used to infuse preoxygenated carrier solutions, such as perfluorocarbon emulsions, directly into the pericardial space; i.e. the space between the pericardium and the epicardial surface.
Inventors
- 👤 Donald R. VanDeripe
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 11:00
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/14; A61M1/32; A61M1/71; A61M1/77; A61M1/84; A61M1/85; A61M25/00; A61M2025/0001; A61M2025/0002; A61M2202/00; A61M2202/04; A61M2202/0468; A61M2202/0476; A61M2205/00; A61M2205/33; A61M2205/3331; A61M2205/3344; A61M2205/3351; A61M2205/3355; A61M2210/00; A61M2210/12; A61M2210/122; A61M3/00; A61M3/02
Claims Analysis
Total Claims: 62
Claim 1
Independent Claim
102 words
A system for oxygenation of the heart, comprising a guiding catheter; a solution delivery catheter; and means for supplying preoxygenated carrier solution through said delivery catheter; wherein said guiding catheter provides means to guide said delivery catheter into the pericardial space between the pericardium and the epicardial surface of the heart; wherein said delivery catheter is constructed so it may be threaded through said guiding catheter and includes means to contact the interior of the pericardial space; and wherein said means for supplying preoxygenated carrier solution comprises means for administering said carrier solution through said delivery catheter directly into the pericardial space.
Claim 2
Independent Claim
102 words
A system for oxygenation of the heart, comprising a guiding catheter; a solution delivery catheter; and means for supplying preoxygenated carrier solution through said delivery catheter; wherein said guiding catheter provides means to guide said delivery catheter into the pericardial space between the pericardium and the epicardial surface of the heart; wherein said delivery catheter is constructed so it may be threaded through said guiding catheter and includes means to contact the interior of the pericardial space; and wherein said means for supplying preoxygenated carrier solution comprises means for administering said carrier solution through said delivery catheter directly into the pericardial space.
Claim 3
Dependent Claim
41 words
A system according to claim 1, wherein said guiding catheter comprises a two lumen catheter, wherein a first lumen is capable of providing a slight vacuum, and a second lumen is capable of guiding said delivery catheter to the pericardial space.
Claim 4
Dependent Claim
42 words
A system according to claim 1, wherein said guiding catheter comprises a concentric dual lumen catheter, wherein an outer lumen is capable of providing a slight vacuum, and an inner lumen is capable of guiding said delivery catheter to the pericardial space.
Claim 5
Dependent Claim
15 words
A system according to claim 1, wherein said guiding catheter includes fiber optic guidance means.
Claim 6
Dependent Claim
40 words
A system according to claim 1, wherein said carrier solution is at least one solution selected from the group consisting of a normal physiological saline, 5% dextrose water, buffer solutions, electrolyte formulations, and emulsions of any aromatic or non-aromatic fluorocarbon.
Claim 7
Dependent Claim
19 words
A system according to claim 5, wherein said carrier solution is isotonic with respect to the cardiac lymph fluid.
Claim 8
Dependent Claim
59 words
A system according to claim 5, wherein said carrier solution is an emulsion of a emulsifying agent and at least one perfluorocarbon compound selected from the group consisting of perfluorodecalin, perfluorooctylbromide, perfluoromethyladamantane, perfluorobromoalkyl-ethers, Fluosol-DA 20%, perfluorohexylether, perfluorobutylethene, perfluoroisoproylhexylethene, perfluorobutylhexylethene, the general classes of perfluoroalkylethers, perfluoroalkylalkenes, perfluoroalkylarylethers, perfluoroalkylarylalkenes, perfluoroarylethers, and perfluoroarylalkenes, and other perfluoronated compounds which can be acceptably emulsified.
Claim 9
Dependent Claim
27 words
A system according to claim 7, wherein said perfluorocarbon compound is at least one compound selected from the group consisting of Fluosol-DA 20%, perfluorooctylbromide, perfluorodecalin, perfluoromethyladamantane, perfluorobromoisobutylether.
Claim 10
Dependent Claim
19 words
A system according to claim 7, wherein said perfluorocarbon compound has a molecular weight of about 400 to 700.
Claim 11
Dependent Claim
19 words
A system according to claim 9, wherein said perfluorocarbon compound has a molecular weight of about 450 to 550.
Claim 12
Dependent Claim
27 words
A system according to claim 7, wherein said emulsifying agent is selected from the group consisting of natural emulsifying agents or synthetic emulsifying agents or combinations thereof.
Claim 13
Dependent Claim
28 words
A system according to claim 11, wherein said emulsifying agent is at least one agent selected from the group consisting of natural egg yolk phospholipid and fluorinated surfactants.
Claim 14
Dependent Claim
22 words
A system according to claim 7, wherein said emulsion is a macroemulsion having an average particle size of 50 to 3000 nanometers.
Claim 15
Dependent Claim
16 words
A system according to claim 13, wherein said average particle size is 100 to 400 nanometers.
Claim 16
Dependent Claim
22 words
A system according to claim 7, wherein said emulsion is a microemulsion having an average particle size of 10 to 100 nanometers.
Claim 17
Dependent Claim
22 words
A system according to claim 15, wherein said emulsion is a microemulsion having an average particle size of 30 to 60 nanometers.
Claim 18
Dependent Claim
33 words
A system according to claim 1, said system being capable of delivering 10 to 2000 milliliters of said carrier solution to the pericardial space over a period of 30 minutes to 6 hours.
Claim 19
Dependent Claim
25 words
A system according to claim 1, wherein said carrier solution is delivered to the pericardial space at a temperature of 20 to 42 degrees centigrade.
Claim 20
Dependent Claim
19 words
A system according to claim 18, wherein said carrier solution is delivered at a temperature of 37 degrees centigrade.
Claim 21
Dependent Claim
20 words
A system according to claim 1, wherein said delivery catheter can deliver therapeutic drugs and nutrients into the pericardial space.
Claim 22
Dependent Claim
33 words
A system according to claim 20, wherein said, therapeutic drugs are selected from the group consisting of lidocaine, throbolytic agents, anti-inflammatory drugs, and drugs which act to attenuate reperfusion damage to the heart.
Claim 23
Dependent Claim
20 words
A system according to claim 20, wherein said nutrients are selected from the group consisting of glucose and fatty acids.
Claim 24
Dependent Claim
25 words
A system according to claim 22, wherein said fatty acids can be chosen from the group consisting of C2 to C18 chain length fatty acids.
Claim 25
Dependent Claim
24 words
A system according to claim 20, wherein said carrier solution, said therapeutic drugs and said nutrients can be delivered simultaneously to the pericardial space.
Claim 26
Dependent Claim
24 words
A system according to claim 1, which may be used following a myocardial infarction to provide oxygen to the ischemic tissue in the myocardium.
Claim 27
Dependent Claim
28 words
A system according to claim 1, which may be used during a percutaneous transluminal coronary angioplasty, so as to prevent the development of ischemic tissue in the myocardium.
Claim 28
Dependent Claim
18 words
A system to claim 5, wherein said carrier solution is hypotonic with respect to the cardiac lymph fluid.
Claim 29
Independent Claim
102 words
A system for oxygenation of body tissue, comprising a guiding catheter; a solution delivery catheter; and means for supplying preoxygenated carrier solution through said delivery catheter; wherein said guiding catheter provides means to guide said delivery catheter into a space between a covering membrane of the tissue and the surface of the tissue; wherein said delivery catheter is constructed so it may be threaded through said guiding catheter and includes means to contact the interior of said space; and wherein said means for supplying preoxygenated carrier solution comprises means for administering said carrier solution through said delivery catheter directly into said space.
Claim 30
Independent Claim
102 words
A system for oxygenation of body tissue, comprising a guiding catheter; a solution delivery catheter; and means for supplying preoxygenated carrier solution through said delivery catheter; wherein said guiding catheter provides means to guide said delivery catheter into a space between a covering membrane of the tissue and the surface of the tissue; wherein said delivery catheter is constructed so it may be threaded through said guiding catheter and includes means to contact the interior of said space; and wherein said means for supplying preoxygenated carrier solution comprises means for administering said carrier solution through said delivery catheter directly into said space.
Claim 31
Dependent Claim
36 words
A system according to claim 28, wherein said tissue is the brain, and said system may be used to administer said carrier solution under the dura into the cerebrospinal fluid covering the surface of the brain.
Claim 32
Independent Claim
108 words
A method of delivering a preoxygenated carrier solution to the heart of a patient, said method comprising; inserting a guiding catheter through the vasculature of the patient until said guiding catheter is in contact with the pericardium; providing a slight vacuum through said guiding catheter so as to separate the pericardium from the heart thereby forming a pericardial space between the pericardium and the epicardial surface of the heart; puncturing the pericardium; threading a delivery catheter through said guiding catheter until said delivery catheter is in contact with the interior of the pericardial space; and delivering said carrier solution through said delivery catheter and into the pericardial space.
Claim 33
Independent Claim
108 words
A method of delivering a preoxygenated carrier solution to the heart of a patient, said method comprising; inserting a guiding catheter through the vasculature of the patient until said guiding catheter is in contact with the pericardium; providing a slight vacuum through said guiding catheter so as to separate the pericardium from the heart thereby forming a pericardial space between the pericardium and the epicardial surface of the heart; puncturing the pericardium; threading a delivery catheter through said guiding catheter until said delivery catheter is in contact with the interior of the pericardial space; and delivering said carrier solution through said delivery catheter and into the pericardial space.
Claim 34
Dependent Claim
20 words
A method according to claim 30, wherein oxygen is provided to ischemic tissue in the myocardium following a myocardial infarction.
Claim 35
Dependent Claim
28 words
A method according to claim 30, wherein oxygen is provided to the myocardium during a percutaneous transluminal angioplasty procedure so as to prevent the development of ischemic tissue.
Claim 36
Dependent Claim
41 words
A method according to claim 30, wherein said guiding catheter comprises a two lumen catheter, wherein a first lumen is capable of providing a slight vacuum, and a second lumen is capable of guiding said delivery catheter to the pericardial space.
Claim 37
Dependent Claim
42 words
A method according to claim 30, wherein said guiding catheter comprises a concentric dual lumen catheter, wherein an outer lumen is capable of providing a slight vacuum, and an inner lumen is capable of guiding said delivery catheter to the pericardial space.
Claim 38
Dependent Claim
15 words
A method according to claim 30, wherein said guiding catheter includes fiber optic guidance means.
Claim 39
Dependent Claim
40 words
A method according to claim 30, wherein said carrier solution is at least one solution selected from the group consisting of a normal physiological saline, 5% dextrose water, buffer solutions, electrolyte formulations, and emulsions of any aromatic or non-aromatic fluorocarbon.
Claim 40
Dependent Claim
19 words
A method according to claim 36, wherein said carrier solution is isotonic with respect to the cardiac lymph fluid.
Claim 41
Dependent Claim
59 words
A method according to claim 36, wherein said carrier solution is an emulsion of a emulsifying agent and at least one perfluorocarbon compound selected from the group consisting of perfluorodecalin, perfluorooctylbromide, perfluoromethyladamantane, perfluorobromoalkyl-ethers, Fluosol-DA 20%, perfluorohexylether, perfluorobutylethene, perfluoroisoproylhexylethene, perfluorobutylhexylethene, the general classes of perfluoroalkylethers, perfluoroalkylalkenes, perfluoroalkylarylethers, perfluoroalkylarylalkenes, perfluoroarylethers, and perfluoroarylalkenes, and other perfluoronated compounds which can be acceptably emulsified.
Claim 42
Dependent Claim
27 words
A method according to claim 38, wherein said perfluorocarbon compound is at least one compound selected from the group consisting of Fluosol-DA 20%, perfluorooctylbromide, perfluorodecalin, perfluoromethyladamantane, perfluorobromoisobutylether.
Claim 43
Dependent Claim
19 words
A method according to claim 38, wherein said perfluorocarbon compound has a molecular weight of about 400 to 700.
Claim 44
Dependent Claim
19 words
A method according to claim 40, wherein said perfluorocarbon compound has a molecular weight of about 450 to 550.
Claim 45
Dependent Claim
27 words
A method according to claim 38, wherein said emulsifying agent is selected from the group consisting of natural emulsifying agents or synthetic emulsifying agents or combinations thereof.
Claim 46
Dependent Claim
28 words
A method according to claim 42, wherein said emulsifying agent is at least one agent selected from the group consisting of natural egg yolk phospholipid and fluorinated surfactants.
Claim 47
Dependent Claim
22 words
A method according to claim 38, wherein said emulsion is a macroemulsion having an average particle size of 50 to 3000 nanometers.
Claim 48
Dependent Claim
16 words
A method according to claim 44, wherein said average particle size is 100 to 400 nanometers.
Claim 49
Dependent Claim
22 words
A method according to claim 38, wherein said emulsion is a microemulsion having an average particle size of 10 to 100 nanometers.
Claim 50
Dependent Claim
22 words
A method according to claim 46, wherein said emulsion is a microemulsion having an average particle size of 30 to 60 nanometers.
Claim 51
Dependent Claim
30 words
A method according to claim 30, wherein 10 to 2000 milliliters of said carrier solution are delivered to the pericardial space over a period of 30 minutes to 6 hours.
Claim 52
Dependent Claim
25 words
A method according to claim 30, wherein said carrier solution is delivered to the pericardial space at a temperature of 20 to 42 degrees centigrade.
Claim 53
Dependent Claim
19 words
A method according to claim 49, wherein said carrier solution is delivered at a temperature of 37 degrees centigrade.
Claim 54
Dependent Claim
18 words
A method according to claim 30, wherein therapeutic drugs and nutrients are also delivered into the pericardial space.
Claim 55
Dependent Claim
33 words
A method according to claim 51, wherein said therapeutic drugs are selected from the group consisting of lidocaine, throbolytic agents, anti-inflammatory drugs, and drugs which act to attenuate reperfusion damage to the heart.
Claim 56
Dependent Claim
20 words
A method according to claim 51, wherein said nutrients are selected from the group consisting of glucose and fatty acids.
Claim 57
Dependent Claim
25 words
A method according to claim 53, wherein said fatty acids can be chosen from the group consisting of C2 to C18 chain length fatty acids.
Claim 58
Dependent Claim
23 words
A method according to claim 51, wherein said carrier solution, said therapeutic drugs and said nutrients are delivered simultaneously to the pericardial space.
Claim 59
Dependent Claim
19 words
A method according to claim 36, wherein said carrier solution is hypotonic with respect to the cardiac lymph fluid.
Claim 60
Independent Claim
102 words
A method of oxygenating body tissue of a patient, said method comprising; inserting a guiding catheter through the vasculature of the patient until said guiding catheter is in contact with a membrane surrounding said body tissue; providing a slight vacuum through said guiding catheter so as to separate the membrane from the tissue surface thereby forming a space between the membrane and the tissue surface; puncturing the membrane; threading a delivery catheter through said guiding catheter until said delivery catheter is in contact with the interior of said space; and delivering said carrier solution through said delivery catheter and into said space.
Claim 61
Independent Claim
102 words
A method of oxygenating body tissue of a patient, said method comprising; inserting a guiding catheter through the vasculature of the patient until said guiding catheter is in contact with a membrane surrounding said body tissue; providing a slight vacuum through said guiding catheter so as to separate the membrane from the tissue surface thereby forming a space between the membrane and the tissue surface; puncturing the membrane; threading a delivery catheter through said guiding catheter until said delivery catheter is in contact with the interior of said space; and delivering said carrier solution through said delivery catheter and into said space.
Claim 62
Dependent Claim
31 words
A method according to claim 57, wherein said tissue is the brain, and said carrier solution is delivered under the dura into the cerebrospinal fluid covering the surface of the brain.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-24 | 1996-11-23 | 1997-05-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-24 | 2000-11-23 | 2001-05-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-24 | 2004-11-23 | 2005-05-25 | $7700.00 | Window Closed / Lapsed |